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Several adaptor proteins have previously been shown to play an important role in the promotion of tumourigenesis. XB130
(AFAP1L2)isanadaptorproteininvolvedinmanycellularfunctions,suchascellsurvival,cellproliferation,migration,andgeneand
miRNA expression. XB130’s functional domains and motifs enable its interaction with a multitude of proteins involved in several
different signaling pathways. As a tyrosine kinase substrate, tyrosine phosphorylated XB130 associates with the p85𝗼 regulatory
subunit of phosphoinositol-3-kinase (PI3K) and subsequently affects Akt activity and its downstream signalling. Tumourigenesis
studies show that downregulation of XB130 expression by RNAi inhibits tumor growth in mouse xenograft models. Furthermore,
XB130 affects tumor oncogenicity by regulating the expression of specific tumour suppressing miRNAs. The expression level and
pattern of XB130 has been studied in various human tumors, such as thyroid, esophageal, and gastric cancers, as well as, soft tissue
tumors. Studies show the significant effects of XB130 in tumourigenesis and suggest its potential as a diagnostic biomarker and
therapeutic target for cancer treatments.
1. Introduction
All cellular functions are regulated through various signaling
pathwaysand protein networks.Accumulatingevidence sug-
g e s t st h a ta d a p t o rp r o t e i n s ,w h i c hc o n t a i nm u l t i p l ep r o t e i n ,
lipid, and DNA interaction domains and motifs, play essen-
tial roles in mediating signal transduction cascades [1, 2].
Adaptor proteins influence cell proliferation, cell survival,
and migration through specific protein-protein and protein-
lipid interactions [3]. In this review, we will define the gene
andproteinstructureofthenoveladaptorprotein,XB130,and
illustrate its role in cellular function and human cancers. We
hope to draw more attention to this signaling molecule and
use it as an example to promote scientific awareness about
the importance of adaptor proteins in signal transduction.
2. XB130: A Novel Gene and Protein
XB130 was first discovered in our research group and has,
subsequently, been studied by several other research groups
and scientific consortia to produce a substantial amount of
information related to XB130 gene structure, variations, and
tissue distribution, which is openly available to the scientific
community.
2.1. XB130 Gene Information. XB130 was discovered through
a molecular cloning process of actin filament associated
protein 1 (AFAP1), and its apparent molecular size is of
130kDa [4]. XB130 is also known as actin filament asso-
ciated protein 1-like 2 (AFAP1L2) [5], KIAA1914 [6], and
PI3KAP [7]. The human xb130 gene (NCBI gene ID 84632;
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Figure 1: XB130 functional domains and motifs. The N-terminus of XB130 contains a proline-rich SH3 domain binding motif at aa 98–107
and three tyrosine containing SH2 domain binding sites at aa 54–57, aa 124–127, and aa 148–15. The first SH2 domain binding site contains
a YXXM motif that binds the SH2 domain in the p85𝗼 subunit of PI3K. In the middle region, there are two PH domains and another SH2
domain binding site at aa 457–460. The C-terminus contains a coiled-coil region.
Unigene cluster Hs.591106; Hugo gene ID 25901; Swiss-
Port ID Q8N4X5) is located on chromosome 10 at 10q25.3
between nucleotide positions 116,054,583 and 116,164,515
(http://www.genecards.org/)[ 8]. Neighboring genes are
NHLRC2, TDRD1 (encodes a scaffold protein), VWA2
(involved in cytoskeleton structure stabilization), ADRB1,
ABLIM1,andPPIAP19.Theproteins,vonWillebrandfactorA
domaincontaining2(VWA2)andactin-bindingLIMprotein
1(ABLIM1),arescaffold-likeproteinswithputativefunctions
in cytoskeleton structural stabilization or remodeling [9, 10].
In addition, at least 10 small nuclear polymorphisms (SNPs)
are present in the xb130genome (http://www.genecards.org),
which may relate to tissue specificity, genetically heritable
disease association, or cancer formation and development.
The human xb130 gene has 19 exons that cover the whole
coding sequence. Putative homologs of XB130 have been
identifiedfromchimpanzee,mouse,rat,bovine,chicken,and
zebra fish.
The transcript size of human xb130 is 3,751bp in length
and encodes an 818-amino-acid protein [4]. The molecular
weight of this protein by western blot analysis is approxi-
mately 130kDa [4]. Furthermore, there are seven putative
splicing variants based on Ensembl sequence alignment
ENSG00000169129 [11]. XB130 also contains several tyrosine
phosphorylation sites and a proline-rich region (PRR) at
the N-terminus, which allows XB130 to interact with Src
Homology 2 (SH2) and Src Homology 3 (SH3) domain
containing proteins, respectively [4]. In addition, there are
two pleckstrin-homology (PH) sequences located in the
m i d d l eo ft h ep r o t e i n ,w h i c ha r ep u t a t i v ep h o s p h o l i p i d
and/or membrane binding domains of XB130. Lastly, a
coiled-coil domain is located at the C-terminal of XB130,
which may be involved in XB130 protein dimerization
(Figure 1).
XB130 mRNA is highly expressed in human thyroid and
spleen and moderately expressed in other organs, such as
brain, pancreas, lung, and kidney [12]. According to the
H u m a nP r o t e i nA t l a sd a t a b a s e ,X B 1 3 0p r o t e i ni sp r e s e n ti n
thyroid, parathyroid, brain, kidney, skin, and gastrointesti-
nal tracks, which include esophagus, stomach, and colon
(http://www.proteinatlas.org/)[ 13]. RNA sequence analysis
by Illumina Body Map also shows expression in lymph node,
adipocytes, adrenal gland, breast, ovary, prostate, and testis
(http://www.genecard.org/)[ 8]. The expression of XB130
proteinhasalsobeenconfirmedwithimmunohistochemistry
staining in human thyroid [14], submucosal glands of esoph-
agus [15], and stomach [16].
2.2. XB130: A Member of AFAP Family. Like many other
discoveries in science, XB130 was discovered serendipitously,
while attempting to clone the human AFAP1 gene [4].
Using the chicken AFAP1 cDNA sequence as a search query,
XB130 was found in the human EST clone library (GenBank
accession1154093)andshowed40%sequencehomologywith
chicken and human AFAP1. Due to XB130’s sequence and
structural similarities to AFAP1, XB130 belongs to the AFAP
family of proteins.
The AFAP family contains three members; AFAP1,
AFAP1L1, and XB130 (AFAP1L2). All AFAP family members
contain two PH domains and a number of SH2 and SH3
binding domain motifs [5]. However, the number and loca-
tion of SH2 and SH3 binding domain motifs, as well as other
unique domains and sequences, differ in each AFAP family
member(Figure 2).Forexample,AFAP1hastwoSH3binding
motifs at the N-terminus, while AFAP1L1 and XB130 have
only one SH3 binding motif [4, 5, 17]. AFAP1 and AFAP1L1
have one SH2 binding motif, whereas XB130 has three at
the N-terminus. The C-termini of AFAP family members
bear more functional differences. For instance, AFAP1 and
AFAP1L1 contain a leucine zipper and an actin-binding
domain (ABD), whereas XB130 only contains a coiled-coil
domain in this region (Figure 2)[ 5]. The unique structural
properties and arrangement of these proteins establish their
localization in different cellular compartments and deter-
mine their binding affinities and interactions with different
moleculesthatareinvolvedinseveralsignalingpathwaysthat
influence different cellular functions. For instance, AFAP1
has a strong association with filamentous actin stress fibers
involved in cytoskeletal remodeling, focal adhesion forma-
tion, and mechanotransduction [17, 18]. AFAP1L1 localizes
at the cell periphery in cytoskeletal outgrowths, known asScientifica 3
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Figure 2: AFAP family proteins. XB130 shares both sequence and structural similarities to the AFAP family of proteins.
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Figure 3: XB130 selectively binds the SH2 domain of several
proteins. GST fusion protein pull-down assay shows that XB130
binds to the SH2 domain of Src, GAP, p85𝗼 s u b u n i to fP I 3 K ,a n d
PLC𝗾.
invadosomes,andinteractswiththeactinpolymerizationand
rearrangement protein, cortactin [5]. XB130, on the other
hand, is predominantly localized in the cytoplasm as an
adaptor protein for signal transduction and regulates cell
proliferation, survival, and gene expression [4, 19]. However,
XB130 is also able to translocate to the cell periphery but
localizes in cytoskeletal outgrowths known as lamellipodia
that function during lateral cell migration [19].
3. XB130: A Novel Adaptor Protein
in Signal Transduction
Although adaptor proteins lack enzyme catalytic activity,
theyfunctionbyinteractingwithvariousmolecularpartners.
XB130 is a good example of an adaptor protein that is able to
activate kinases and affect downstream proteins in signaling
pathways, leading to changes in cellular function.
3.1. XB130 Activates c-Src and Enhances Src-Mediated
AP-1/SRE Transcriptional Activation. Src protein tyrosine
kinases are important signaling molecules that are involved
in the regulation of multiple cellular functions [20]. AFAP1
is a known substrate and activator of Src protein tyrosine
kinase [17]. Similar to AFAP1, XB130 is also a tyrosine
kinase substrate. In vitro coexpression of XB130 with a
single tyrosine kinase, such as Src [4], RET/PTC [12],
Lck [18], and several other protein tyrosine kinases (e.g.,
EGFR, Abl, and ERBB2), results in XB130 phosphorylation
[21]. The XB130-Src interaction was further shown using
coimmunoprecipitation (Co-IP) in COS-7 cells that were
cotransfected with both XB130 and c-Src. Coexpression of
c-Src and XB130 resulted in activation of c-Src both in vivo
and in vitro [4]. XB130 also binds to the SH2 domain of Lck
kinase, which is expressed in colorectal cancer cells [22].
Using the GST-fusion protein pull-down assay, it has been
shown that XB130 binds SH2 domain containing proteins,
suchasSrc,GAP,p85𝗼regulatorysubunitofPI3K,andPLC𝗾
(Figure 3)[4,12].TheseresultsindicatethattheSH2andSH3
binding motifs of XB130 are critical for the interaction of
XB130 with multiple kinases and may lead to the regulation
of cell homeostasis.
Src kinase activity affects cell mitogenesis and transfor-
mation by regulating the transcriptional elements, SRE and
AP-1 [23–25], as well as the Smad binding element (SBE)
involvedinTGF-𝗽mediatedsignaltransduction[26].Studies
have shown that XB130 activates c-Src and subsequently
inducesAP-1andSREtransactivation.However,XB130inter-
action with c-Src does not induce Smad-mediated transcrip-
tional activation [4]. The AP-1 transcription factor is known
tobindtothepromoterregionofthechemokine,interleukin-
8(IL-8),whichisproducedbylungepithelialcellsinresponse
to localized infection and inflammation [27]. Introduction
of a Src inhibitor or downregulation of XB130 with small
interferingRNA (siRNA) reduced IL-8 productionin human
lung epithelial A549 cells [4]. Consequently, XB130 may be
highly involved in inflammation and the innate immune
response via the SRE and AP-1 transcriptional elements.
3.2. XB130 Binds to the p85𝗼 Subunit of PI3K and Regulates
PI3K Downstream Signaling. Northern blot assay revealed
that the highest level of XB130 mRNA is expressed by the
thyroid in human [12]. A thyroid specific tyrosine kinase,
RET/PTC, is an oncogene due to chromosomal rearrange-
ment, which plays a crucial role in thyroid cancer cells by
controlling cell differentiation and proliferation [28]. Co-
IP studies show that exogenously overexpressed RET/PTC
and XB130 interact in thyroid papillary carcinoma cells.
RET/PTC mediates tyrosine phosphorylation of the YxxM
motif of XB130 at tyrosine residue 54 [12]. This YxxM motif
is the primary binding site of the p85𝗼 subunit of PI3K.
Consequently,RET/PTCpromotedtheassociationoftheSH2
domain of the p85𝗼 subunit of PI3K with tyrosine phospho-
rylated XB130 [12]( Figure 3). Furthermore, knockdown of
XB130 in TPC1 papillary thyroid carcinoma cells expressing
RET/PTC resulted in reduced Akt phosphorylation at serine
residue473,whichblockedcellcycleprogressionandreduced
cell survival [12].
In normal rat thyroid FRTL-5 cells, cyclic adenosine
monophosphate (cAMP) treatment increased tyrosine phos-
phorylation of a 125kDa protein (p125) and its association4 Scientifica
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Figure 4: Summary of XB130 cellular functions.
with the p85𝗼 subunit of PI3K [7]. Matrix assisted laser
desorption ionization-time of flight (MALDI-TOF) mass
spectrometry identified p125 as a rat ortholog of human
XB130 (which was labeled as PI3K-associated protein or
PI3KAP) [7]. Furthermore, cAMP stimulation increased
both XB130 mRNA and protein expression, as well as Src
mediated tyrosine phosphorylation of the YxxM motif,
w h i c hr e s u l t e di nb i n d i n gt ot h ep 8 5 𝗼 s u b u n i to fP I 3 K[ 7].
Inhibition or knockdown of Src kinase abolished cAMP-
induced tyrosine phosphorylation of XB130, XB130 interac-
tion with the p85𝗼 s u b u n i to fP I 3 K ,a n dd e c r e a s e dP I 3 K
activity [7]. In addition, knockdown of XB130 was associated
with reduced potentiation of cell synthesis and reduced
cyclin D1 protein expression [7]. The evidence presented in
this study suggests that XB130 plays an important role in
cell cycle progression and proliferation in normal thyroid
cells.
These studies demonstrate that Src or other tyrosine
kinase mediated-tyrosine phosphorylations of the YxxM
motif at the N-terminus of XB130 are a critical event for
XB130 binding to the p85𝗼 s u b u n i to fP I 3 K .Th ea s s o c i a t i o n
of XB130 with PI3K is important in the regulation of cell
proliferation, cell cycle progression, and cell survival of both
normal and cancer cells.
4. Cellular Functions of XB130
Adaptor proteins are essential in the maintenance of normal
cellular physiology and homeostasis by acting as scaffolds
and transmitters that bind and translocate molecules to
larger complexes or cellular compartments to aid in signal
transduction. By acting as an upstream regulator of PI3K,
XB130 plays an important role in mediating cell survival and
proliferationthroughAktpathways[21]andincellmigration
through Rac-dependent pathways [12, 19]. The role of XB130
is not limited to protein activity and several studies have
shown that XB130 also participates in the regulation of gene
expression [14]( Figure 4).
4.1. XB130 Modulates Cell Proliferation and Survival. In
human thyroid cancer cells, phosphorylated XB130 controls
PI3K/Akt activity and subsequently regulates cell prolifera-
tion and survival [12]. Other studies have observed similar
results using TE2, TE5, and TE9 esophageal squamous car-
cinoma cells [15], as well as SGC7901 (malignant, metastatic
type) and MNK45 (solid tumor under hypoxia type) gastric
cancer cell lines [16].
The Akt pathway bears a strong association with cell
proliferation and cell survival [29, 30]. To investigate the
roles of XB130 in cell survival and proliferation, PI3K/Akt
downstream signal pathway proteins were studied in WRO
thyroid cancer cells and A549 lung adenocarcinoma cells
[21].TheXB130-p85𝗼associationwasdetectedinbothcancer
cell lines using Co-IP. Downregulation of XB130 reduced
phosphorylation of Akt and the Akt substrate, glycogen
synthase kinase 𝗽 (GSK3𝗽)[ 12], which is a serine-threonine
kinase that inhibits glycogen synthase assisting in energyScientifica 5
metabolism and cell cycle progression [31]. Reduced phos-
phorylation of Akt resulted in inhibition of Akt activity [12].
DownregulationofXB130causedablockadeofcellcyclepro-
gressionfromG1toSphaseinbothWROandA549cells[12].
In addition, measurement of the cell proliferation markers,
Ki67 and proliferating cell nuclear antigen (PCNA), showed
that knockdown of XB130 reduces cell proliferation [12].
Studies reported that activated Akt induces phosphorylation
of p21 Cip/WAF1 (or cyclin dependent kinase interacting
protein-1, CDKI-1) and p27 Kip1 (or cyclin dependent kinase
inhibitor-1B, CDKI-1B) [21, 32]. Moreover, the accumulation
of phosphorylated p21 Cip/WAF1 and p27 Kip1 proteins in
the cytoplasm promotes cell survival [32]. RNAi silencing of
XB130 reduced phosphorylation of p27 Kip1, p21 Cip/WAF1,
a n dF O X O 3 aa n di n h i b i t e dc e l ls u r v i v a li nW R Oa n dA 5 4 9
cells [21]. These results suggest that XB130 regulates cell
proliferation and cell survival by mediating the PI3K/Akt
pathway and its downstream proteins, p21 Cip/WAF1, p27
Kip1,andFOXO3a,inthyroidandlungadenocarcinomacells.
Furthermore, XB130 downregulation in combination
with either extrinsic (FasAb) or intrinsic (staurosporine)
apoptotic stimuli results in enhanced apoptosis of WRO and
A549 cells [21]. The activation of caspase-8 is essential for
the progression of extrinsic apoptosis, whereas the activation
of caspase-9 is essential for the intrinsic apoptotic pathway
[33]. Interestingly, XB130 knockdown cells showed increased
levels of cleaved caspase-8 and caspase-9 in WRO cells but
decreased procaspase-8 expression and increased caspase-9
cleavage in A549 cells [21]. Other studies suggest that Akt
phosphorylates procaspase-9 to prevent its cleavage [34]a n d
that Akt inhibition enhances TRAIL-induced activation of
caspase-8 [35]. Therefore, the effects of XB130 on apoptosis
or cell death may also be attributed to Akt activity and
Akt downstream proteins. However, more experiments are
required to better understand this mechanism.
4.2. XB130 Controls Expression of Genes Related to Prolifera-
tion and Survival. XB130 was previously shown to activate
the transcription factors SRE and AP-1, suggesting that
XB130 may play a role in the regulation of gene expression.
Microarray analysis of XB130 shRNA transfected WRO cells
compared to vector transfected control cells demonstrated
thatXB130knockdownhasasignificanteffectongeneexpres-
sion profiles [14]. In total, 57 genes with cell proliferation
or survival related function showed a downregulated change
in XB130 knockdown cells [36]. Ingenuity pathway analysis
listed the top molecular and cellular functions related to
XB130 knockdown as cellular growth, proliferation, and cell
cycle [36].
MicroRNAs (miRNA, miRs) are a class of small, noncod-
ing RNA molecules regulating gene expression by mediating
the degradation of specific target genes [37]. The expression
levels of multiple miRNAs were altered in XB130 knockdown
WRO cells [36]. The three miRNAs miR-33a, 149a, and
193a-3p, which showed changes in expression level after
XB130 downregulation, exhibit tumor suppressive function
in thyroid cancer cells [38–40]. The expression of both
the pri-miRNA and mature miRNA of miR-33a, 149a, and
193a-3p was increased in XB130 knockdown WRO cells
[41]. Overexpression of miR-33a, 149a, and 193a-3p miRNA
specific mimics led to protein level reduction of their cor-
responding targets Myc, SLC7A5, and FOSL1 [41]. Further
studies indicated that these miRNAs inhibit their target
gene expression by directly binding to the 3
򸀠UTR region
of the target gene mRNAs causing translation retardation
[41]. The regulation of these miRNAs suggests that XB130
is an important mediator at both the gene and protein
level.
4.3. XB130 Mediates Cytoskeletal Reorganization during Cell
Migration. A dynamic cytoskeleton rearrangement is essen-
tial for cell motility. The complex nature of cytoskele-
tal rearrangement and remodeling involves a plethora of
molecules. Many adaptor proteins participate in the for-
mation of cytoskeletal outgrowths, such as lamellipodia,
membrane ruffles, and podosomes, which are important for
cell motility [42–45]. XB130 is also involved in cytoskeleton
reorganization.
Although XB130 is known as AFAP1L2, its intracellular
distribution is very different from that of AFAP1. As men-
tioned earlier, AFAP1 and AFAP1L1 contain a well-defined
actin-binding motif in their C-termini (Figure 2). The actin-
binding motif in AFAP1 is responsible for its binding to
F-actin stress fibers and organization of microfilaments
[46]. In contrast, XB130 does not possess an actin-binding
motif. In BEAS-2B human lung epithelial cells, XB130 is
loca tedinthecytoplasmanddispla ysapuncta tedistribution,
w h e r e a sA F A P 1a p p e a r st oc o l o c a l i z ew i t ha c t i ns t r e s sfi b e r s
[4]. However, in EGF stimulated rat mammary carcinoma
(MTLn3) cells, XB130 shows a translocation from cytoplasm
to cell periphery [19].Asimilarresultisobservedinphorbol-
myristateacetate(PMA)treatedTPC1thyroidcancercells,in
whichXB130appearstotranslocatetorearrangedcytoskeletal
structures at the cell periphery [19]. Moreover, when TPC1
cells were transfected with constitutively activated (CA)
formsofRhoGTPase,RhoA(Q63L)orRac1(Q61L),onlythe
CA-Rac1 expressing cells showed translocation of XB130 to
the cell periphery [19]. These motility-induced cells lacked
defined central stress fibers but formed lamellipodia at the
cell periphery. Interestingly, XB130 translocation did not
take place in CA-Rho expressing cells, which maintained
strong stress fiber formation. We speculate that XB130’s
interaction with Rac, which promotes the formation of
highly branched F-actin meshwork, results in the association
of XB130 to lamellipodia with defined branched F-actin
structure. Immunofluorescence (IF) confocal microscopy
analysis using cells transfected with different XB130 deletion
constructs indicates that both the N-terminus (containing
167aa) and C-terminus (containing 63aa) are required for
XB130movementtothecellperiphery[19].Thetranslocation
of XB130 to lamellipodia suggests that XB130 has a putative
functionincellmigration.DownregulationofXB130inTPC1
cells results in decreased wound closure area and increased
time for wound closure [12], as well as inhibited invasion
of cells through a matrigel coated Boyden chamber, reduced
lamellipodial persistence, and reduced cell spreading [19].6 Scientifica
Thus, XB130 is a novel Rac GTPase-mediated cytoskele-
ton remodeling protein with high translocation affinity to
lamellipodia that contain branched F-actin. Furthermore,
XB130 impacts several characteristics of cell migration and
invasiveness, such as type and persistence of cytoskeleton
structures, cell spreading, and direction of migration, and
may prove to be an important feature in tumourigenesis and
cancer cell metastasis.
5. Clinical Significance of XB130 in Cancer
Deregulation of adaptor proteins is highly related to the
abnormality of cellular functions and leads to a spectrum of
diseases, including cancer. Many studies have demonstrated
that adaptor proteins are also involved in oncogenic signal
transduction pathways. For example, the expression of adap-
tor protein, SH2B1, is elevated in non-small cell lung cancer
(NSCLC) tissues [47]. SH2B1’s overexpression is considered
to be an independent prognostic factor for patients with
NSCLC [47]. More interestingly, the adaptor proteins in the
AFAP family, AFAP1 and AFAP1L1, are also involved in
cancer. AFAP1, for instance, plays a significant role in breast
cancer cell adhesion and in the tumorigenesis of prostate
cancer [48, 49], whereas AFAP1L1 has been found to be
involved in spindle cell sarcomas [50, 51]. Like these AFAP
family members, several recent studies indicate that XB130 is
also involved in tumorigenesis [36].
5.1. XB130 in Human Gastrointestinal Cancers. The first clue
that XB130 may be involved in tumorigenesis is from a pro-
teomics study investigating novel biomarkers for colorectal
cancers. The Src family member, Lck, was not detectable
in normal colonic epithelium but was aberrantly expressed
in a subset of colorectal cancer cells [22]. Using mass
spectrometry, XB130 was identified as one of the tyrosine
phosphorylated proteins that interacts with Lck in colorectal
cancercells,andthusXB130maybeconsideredasapotential
colorectal cancer marker [22]. The oncogenic role of XB130
is also revealed in other gastrointestinal cancers. In normal
esophagus, immunohistochemical staining of XB130 protein
expression is very low in the epithelium [15]. However,
elevated XB130 protein expression was detected in various
human esophageal squamous carcinomas [15]. Furthermore,
thelocalizationofXB130inthenucleusofhumanesophageal
squamous carcinoma cells was associated with a shorter 5-
year survival rate [15]. Moreover, XB130 protein expression
was also reported in gastric cancer tissues. By analyzing gas-
tric cancer samples collected from 411 patients with various
stages of cancer, lower protein expression of XB130 in tissue
samples was significantly correlated with decreased overall
survival time and shorter disease-free period after surgical
operation [16]. Thus, it is apparent that XB130 has a major
impact on both the progression of human gastrointestinal
cancers and the survival of patients.
5.2. XB130 in Thyroid Cancers. The first in vivo study of
XB130 in thyroid cancer tumorigenesis was done by injecting
XB130 shRNA stably transfected WRO thyroid cancer cells
subcutaneously into nude mice [14]. The volume of tumors
formed from XB130 knockdown WRO cells was significantly
smaller than those formed from WRO cells transfected with
a control vector [14]. The absence of XB130 led to a reduction
intumorgrowthaccompaniedwithreducedcellproliferation
and enhanced apoptosis [14]. A human thyroid tissue-array
revealed that XB130 protein is located in the cytoplasm of
thyroid follicular cells both in normal thyroid tissue and in
papillary thyroid carcinoma [12]. Semiquantitative analysis
of cytoplasmic intensity showed that XB130 expression in
papillary and anaplastic/insular carcinoma was significantly
lower than that in normal tissue and benign lesions [14]. The
reduced expression of XB130 in thyroid cancer cells may be
due to the disruption of normal tissue structure. In normal
thyroid tissue, XB130 is highly expressed and is an essential
protein in maintaining normal physiological activity of the
thyroid. However, by suppressing XB130 expression, cancer
cells may manipulate XB130 mediated signal transduction
pathways that control proliferation, survival, and migration
to favor tumor growth and invasion.
5 . 3 .X B 1 3 0i nO t h e rT y p e so fT u m o r s . Soft tissue tumors are a
group of neoplasias with different histological and biological
features. Gene expression profiling of 102 representative
tumor samples varying from benign, locally confined tumors
to very aggressive and metastatic tumors revealed that XB130
isoneofsixhighlyexpressedgenesrelatedtolocalaggressive-
ness of soft tissue tumors [52]. The gene expression of XB130
w a sa l s oe x a m i n e di nh u m a nh e p a t o c e l l u l a rc a r c i n o m a .
Although positive expression of XB130 mRNA was found in
75% of the samples analyzed, the protein expression levels of
XB130 in tissue samples were not associated with the prog-
n o s i so fp a t i e n t sw i t hh e p a t o c e l l u l a rc a r c i n o m a[ 53]. Based
on the Sanger Institute database (http://www.sanger.ac.uk/),
XB130 somatic mutations were detected in a variety of tumor
s a m p l e sf r o ml u n g ,l a r g ei n t e s t i n e ,o v a r y ,s k i n ,p r o s t a t e ,a n d
endometrial tissues. Among these tumors, 70% of the iden-
t i fi e dc a s e sa r ec a u s e db ys u b s t i t u t i o nm i s s e n s em u t a t i o n si n
the XB130 gene. This new information elucidates an entirely
new approach to identify XB130’s roles, impact, and tissue
specificity in tumorigenesis and cancer progression.
6. Prospective
As a newly discovered gene and protein, XB130 has only
been studied in vitro and in vivo by a few research groups.
Its functions in the regulation of intracellular signal trans-
duction pathways and gene expression and cellular functions
are largely unknown. Thus, our knowledge on XB130 in
vivo is even more limited by the lack of transgenic animals
and clinical studies. Further investigation of XB130 and its
interacting molecules and related pathways will be fruitful.
6.1. Cellular and Molecular Biological Studies. From a cell
biology point of view, we are aware that XB130 is an adaptor
protein and as such may have many interactors. However,
many of its protein and lipid-binding partners are largely
unknown. We suggest that yeast-two-hybrid screening andScientifica 7
other proteomic approaches should be used to identify
XB130’s protein-binding partners. Secondly, XB130 contains
two PH domains, which are involved in protein-lipid inter-
actions. Exploring the role of XB130 in membrane biology,
such as membrane receptors and ion channels, as well as
membrane structures related to secretion, endocytosis, and
exocytosis, should be considered for future investigation.
Finally ,theProteinAtlasdatabaseshowsthatXB130ispresent
in the nuclei of A-431 human epidermoid carcinoma cells,
U-2 OS human bone osteosarcoma cells, and U-251 human
neuronal glioblastoma cells. Additionally, an immunohisto-
chemicalstainingofhumanesophagealsquamouscarcinoma
also revealed XB130 nucleic localization [15]. These sources
suggest that XB130 may have potential functions in the
nucleus of specific cancer cells.
6.2. Physiological Functions of XB130 In Vivo. Human XB130
mRNA and protein are highly expressed in thyroid and
spleen. The thyroid is a major organ that controls body
metabolism, energy consumption, and protein synthesis.
Dysregulation of XB130 expression in thyroid tissue may
result in the dysfunction of the thyroid leading to devel-
opmental retardation and hormone disorders. Interestingly,
immunohistochemistry staining reveals that XB130 protein
expression is high in thyroid follicular cells [12], which are
responsible for the synthesis and secretion of thyroid hor-
mones, thyroxine (T4), and triiodothyronine (T3). During
thyroid hormone synthesis, numerous proteins are involved
iniontransportationacrossthecellmembrane,iodideoxida-
tion,andendocytosis.Thus,XB130,asanadaptorprotein,has
the potential to be involved in thyroid hormone production,
accumulation, and release. The other organ of significance
to XB130 expression is the spleen, which is involved in the
removal of red blood cells and recycling of iron, as well as
the synthesis of antibodies and storage of monocytes [54].
In the spleen, XB130 may play a pivotal role in immune
function. As we have seen before, XB130 mediates the release
of IL-8, which hints to the role of XB130 in the innate
immune response. More impressive is the fact that XB130
is also highly expressed in the epithelial cells of thyroid
tissue [14], esophageal submucosal glands [15], and the
intestine (http://www.sanger.ac.uk/). Consequently, XB130
may also participate in epithelial cell repair and regeneration
by protecting cells from apoptosis and by promoting cell
cycle progression and cell migration events in tissues after
injury. There are many possible XB130 related tissue-specific
mechanisms that are yet to be explored. Future studies of
XB130’s role in specific tissues and organs may benefit from
the use of XB130 knockin or knockout transgenic mice.
6.3. XB130 in Tumorigenesis. XB130 expression profiles in
multiple cancer tissues reveal that XB130 is involved in
tumorigenesis. However, whether it functions as a tumor
promoter or a tumor suppressor is still unknown. According
toinvitrodata,XB130promotescellproliferationandsurvival
notonlyby regulatingPI3K activityandtheAktpathway,but
also by regulating miRNA expression in various cancer cells.
MiRNA functional studies are an emerging area of research
in tumorigenesis and cancer development and a significant
number of miRNAs have been identified as either tumor
suppressors or oncogenes [37]. Based on recent findings,
we speculate that XB130 affects cancer cell proliferation and
survival by modulating the expression of possible tumor
suppressing miRNAs and the translation of their target
proteins.
XB130 may also directly play a role as a tumor sup-
pressor. Several sources have demonstrated that the XB130
protein expression level is higher in normal tissue or less
invasive tumors than in malignant, cancer tissues [14, 52].
Moreover, elevated expression of XB130 was associated with
better clinical outcomes in gastric cancer [16]. However,
more detailed genetic and epigenetic studies are required to
elucidate XB130’s roles in different tissue types of tumors and
at different stages of cancer progression.
The significant effects of XB130 in tumorigenesis and
during cancer development in different tissues support its
potential as a diagnostic biomarker and therapeutic target.
U s i n gb o t hc e l lb i o l o g yt e c h n i q u e sa n da n i m a lm o d e l s ,
the roles of XB130 should be further investigated to verify
XB130’s potential as a diagnostic marker in the prevention
of cancer and as a therapeutic target for the continued
survival of cancer patients. These studies will also elucidate
the molecular mechanisms mediated by the novel adaptor
protein, XB130.
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